Shares of Amarin Corp. plc skyrocketed as high as 67 percent Monday after the biotech reported that its prescription grade omega-3 fatty acid drug AMR101 (ethyl icosapentate) not only lowered triglycerides in patients with high levels during a pivotal Phase III study, but the drug did not increase low-density lipoprotein cholesterol (LDL-C) – a claim GlaxoSmithKline plc's Lovaza (omega-3-acid ethyl esters) cannot make. (BioWorld Today) Read More
